Table 2 Forest plots summary
Endpoints | Single high-dose statin | Placebo | Odds ratio/ mean differences [95% CI] | P values |
|---|---|---|---|---|
Major adverse cardiovascular events (MACE) | 8.18% (231/2824) | 13.30% (383/2879) | OR 0.50 [0.35–0.71] | 0.0001* |
Myocardial infraction (MI) | 3.03% (71/2347) | 5.07% (122/2406) | OR 0.57 [0.42–0.77] | 0.0002* |
All-cause mortality | 1.56% (44/2824) | 2.75% (79/2872) | OR 0.56 [0.39–0.81] | 0.0002* |
Target vessel revascularization (TVR) | 1.47% (27/1838) | 2.47% (47/1900) | OR 0.56 [0.35–0.92] | 0.02* |
TIMI flow grade 3 | 95.07% (2834/2981) | 93.92% (2857/3042) | OR 1.20 [0.94–1.53] | 0.14 |
Left ventricular ejection fraction (LVEF) | – | – | OR: 2.19 [-0.97–5.34] | 0.17 |
MACE subgroup analysis | ||||
 80 mg atorvastatin | 8.61% (196/2277) | 12.30% (281/2284) | OR 0.66 [0.54–0.81] | < 0.0001* |
 40 mg rosuvastatin | 6.40% (35/547) | 17.14% (102/595) | OR 0.19 [0.07–0.54] | 0.002* |
 Asian population | 8.53% (91/1066) | 16.69% (186/1114%) | OR 0.38 [0.20–0.70] | 0.002* |